{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:58:49Z","timestamp":1781848729881,"version":"3.54.5"},"reference-count":40,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["PracticalResearchProjectforRare\/IntractableDiseases(InnovationResearchinAutoimmuneDiseases)"],"award-info":[{"award-number":["PracticalResearchProjectforRare\/IntractableDiseases(InnovationResearchinAutoimmuneDiseases)"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K08263"],"award-info":[{"award-number":["JP18K08263"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18H02829"],"award-info":[{"award-number":["JP18H02829"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Dermatomyositis (DM) is an inflammatory myopathy with characteristic skin manifestations, the pathologies of which are considered autoimmune diseases. DM is a heterogeneous disorder with various phenotypes, including myositis, dermatitis, and interstitial lung disease (ILD). Recently identified myositis-specific autoantibodies have been associated with distinct clinical features. For example, anti-melanoma differentiation-associated protein 5 antibodies have a high specificity for clinically amyopathic DM presenting rapidly progressive ILD. Furthermore, anti-transcriptional intermediary factor 1\u03b3 antibodies found in patients with juvenile and adult DM are closely correlated with malignancies, especially in elderly patients. Finally, patients with anti-aminoacyl-transfer RNA synthetase antibodies share characteristic clinical symptoms, including myositis, ILD, arthritis\/arthralgia, Raynaud\u2019s phenomenon, and fever; thus, the term \u201canti-synthetase syndrome\u201d is also used. With a focus on the characteristic cutaneous manifestations in each subgroup classified according to myositis-specific autoantibodies, we introduce the findings of previous reports, including our recent analysis indicating that skin eruptions can be histopathologically classified into myositis-specific autoantibody-associated subgroups and used to determine the systemic pathologies of the different types of antibody-associated DM.<\/ns4:p>","DOI":"10.12688\/f1000research.20646.1","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T11:45:07Z","timestamp":1574336707000},"page":"1951","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Cutaneous manifestations of dermatomyositis characterized by myositis-specific autoantibodies"],"prefix":"10.12688","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5398-0773","authenticated-orcid":false,"given":"Naoko","family":"Okiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"30-9","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research.","volume":"77","author":"J Lilleker","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1212\/NXI.0000000000000172","article-title":"Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease.","volume":"2","author":"A Mammen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"ref-3","doi-asserted-by":"publisher","DOI":"10.1186\/ar4198","article-title":"Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?","volume":"15","author":"S Tansley","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"269-78","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis.","volume":"14","author":"I Lundberg","year":"2018","journal-title":"Nat Rev Rheumatol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"636-44","DOI":"10.1097\/BOR.0000000000000329","article-title":"Recent advances in dermatomyositis-specific autoantibodies.","volume":"28","author":"M Fujimoto","year":"2016","journal-title":"Curr Opin Rheumatol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"1571-6","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis.","volume":"52","author":"S Sato","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1627-31","DOI":"10.1007\/s10067-015-2935-9","article-title":"Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis\/dermatomyositis.","volume":"34","author":"Z Chen","year":"2015","journal-title":"Clin Rheumatol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"517-23","DOI":"10.1590\/abd1806-4841.20186803","article-title":"Prevalence and reactivity of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) autoantibody in Brazilian patients with dermatomyositis.","volume":"93","author":"I Borges","year":"2018","journal-title":"An Bras Dermatol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"48-55","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.","volume":"101","author":"Z Betteridge","year":"2019","journal-title":"J Autoimmun."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1307-15","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum.","volume":"65","author":"J Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1316-24","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.","volume":"65","author":"Z Chen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"1713-9","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.","volume":"49","author":"T Gono","year":"2010","journal-title":"Rheumatology (Oxford)."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"784-91","DOI":"10.1093\/rheumatology\/keu385","article-title":"Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.","volume":"54","author":"N Kobayashi","year":"2015","journal-title":"Rheumatology (Oxford)."},{"key":"ref-14","doi-asserted-by":"publisher","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.","volume":"16","author":"S Tansley","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"495-512","DOI":"10.1111\/nan.12528","article-title":"Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features.","volume":"45","author":"S Yasin","year":"2019","journal-title":"Neuropathol Appl Neurobiol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"25-8","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy.","volume":"46","author":"K Kaji","year":"2007","journal-title":"Rheumatology (Oxford)."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"3682-9","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis.","volume":"54","author":"I Targoff","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"513-22","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins.","volume":"64","author":"M Fujimoto","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"2954-62","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3.","volume":"65","author":"D Fiorentino","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"648-51","DOI":"10.1002\/acr.23325","article-title":"Association of Anti-Transcription Intermediary Factor 1\u03b3 Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.","volume":"70","author":"P Venalis","year":"2018","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"e0154746","DOI":"10.1371\/journal.pone.0154746","article-title":"Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies.","volume":"11","author":"N Mugii","year":"2016","journal-title":"PLoS One."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"449-55","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis.","volume":"72","author":"D Fiorentino","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"391-8","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: A multicenter cross-sectional study.","volume":"147","author":"Y Hamaguchi","year":"2011","journal-title":"Arch Dermatol."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"256-262","DOI":"10.2340\/00015555-3091","article-title":"Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.","volume":"99","author":"M Best","year":"2019","journal-title":"Acta Derm Venereol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"24-38","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: Pathogenesis, clinical and autoantibody phenotypes, and outcomes.","volume":"280","author":"L Rider","year":"2016","journal-title":"J Intern Med."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"883-91","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: A meta-analysis revisiting the so-called antisynthetase syndrome.","volume":"13","author":"J Lega","year":"2014","journal-title":"Autoimmun Rev."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"279-89","DOI":"10.1016\/s0092-8674(00)81758-4","article-title":"The dermatomyositis-specific autoantigen mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities.","volume":"95","author":"Y Zhang","year":"1998","journal-title":"Cell."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"2547-51","DOI":"10.3899\/jrheum.090461","article-title":"Clinical and serologic characterization of an Argentine pediatric myositis cohort: Identification of a novel autoantibody (anti-MJ) to a 142-kDa protein.","volume":"36","author":"G Espada","year":"2009","journal-title":"J Rheumatol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"710-3","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: Possible association with malignancy.","volume":"71","author":"Y Ichimura","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"3132-7","DOI":"10.1002\/art.22862","article-title":"Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis.","volume":"56","author":"Z Betteridge","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"1414-1415","DOI":"10.1111\/bjd.17026","article-title":"Diffuse erythema with 'angel wings' sign in Japanese patients with anti-small ubiquitin-like modifier activating enzyme antibody-associated dermatomyositis.","volume":"179","author":"S Inoue","year":"2018","journal-title":"Br J Dermatol."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"25-34","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study.","volume":"65","author":"D Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"667-72","DOI":"10.1002\/acr.22498","article-title":"Cutaneous ulceration in dermatomyositis: Association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease.","volume":"67","author":"N Narang","year":"2015","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"1442-1446","DOI":"10.1111\/bjd.15499","article-title":"Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules\/papules.","volume":"177","author":"H Koguchi-Yoshioka","year":"2017","journal-title":"Br J Dermatol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"769-775.e2","DOI":"10.1016\/j.jaad.2017.10.034","article-title":"Re-examining mechanic's hands as a characteristic skin finding in dermatomyositis.","volume":"78","author":"J Concha","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"11-8","DOI":"10.1016\/j.clim.2018.11.008","article-title":"Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: A meta-analysis of 20 cohorts.","volume":"198","author":"L Zhong","year":"2019","journal-title":"Clin Immunol."},{"key":"ref-37","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.1668","article-title":"Distinct Histopathologic Patterns of Finger Eruptions in Dermatomyositis Based on Myositis-Specific Autoantibody Profiles.","author":"N Okiyama","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"992-999","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal Muscle Involvement in Antisynthetase Syndrome.","volume":"74","author":"E Noguchi","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"493-500","DOI":"10.1212\/WNL.0000000000003568","article-title":"Sarcoplasmic MxA expression: A valuable marker of dermatomyositis.","volume":"88","author":"A Uruha","year":"2017","journal-title":"Neurology."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"1090-1098","DOI":"10.1111\/bjd.16917","article-title":"Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis.","volume":"180","author":"S Zhang","year":"2019","journal-title":"Br J Dermatol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-1951\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1951\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1951\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T04:00:19Z","timestamp":1574395219000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-1951\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":40,"URL":"https:\/\/doi.org\/10.12688\/f1000research.20646.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.22708.r56808","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.22708.r56810","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.22708.r56809","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-1951\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.22708.r56810, Guochun Wang, Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, 22 Nov 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1951\/v1#referee-response-56810","order":0,"name":"referee-response-56810","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.22708.r56809, Samuel Katsuyuki Shinjo, Division of Rheumatology, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, 22 Nov 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1951\/v1#referee-response-56809","order":1,"name":"referee-response-56809","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.22708.r56808, Lisa Christopher-Stine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA, 22 Nov 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1951\/v1#referee-response-56808","order":2,"name":"referee-response-56808","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The research included in this article was supported by JSPS KAKENHI (grant numbers JP 18K08263 and JP 18H02829) and by an AMED Practical Research Project for Rare\/Intractable Diseases (Innovation Research in Autoimmune Diseases). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}